Combining radiation therapy, CART-19 therapy, and gut microbiome changes to treat lymphoma
Targeting Lymphoma: A Multimodal Approach using Radiation, CART-19 Therapy, and Gut Microbiome Modulation
This study is exploring a new way to treat lymphoma by using a combination of radiation therapy, a special immune treatment called CART-19, and an antibiotic to adjust the gut bacteria, all aimed at helping your body fight the cancer better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11049595 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating lymphoma by combining radiation therapy with CART-19 therapy and modulation of the gut microbiome using oral Vancomycin. The study aims to enhance the body's immune response against tumors by selectively depleting certain gut bacteria, which may improve the presentation of tumor-associated antigens to immune cells. Patients will be monitored for improvements in tumor response and overall survival as a result of this combined treatment strategy. The research builds on previous findings that showed promising results in preclinical models and early-stage clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lymphoma who are eligible for radiation therapy and CART-19 therapy.
Not a fit: Patients with other types of cancer or those who are not eligible for radiation or CART-19 therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for lymphoma patients, potentially improving survival rates and quality of life.
How similar studies have performed: Previous studies have shown success with similar approaches, particularly in enhancing antitumor responses through gut microbiome modulation and combination therapies.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Facciabene, Andrea — University of Pennsylvania
- Study coordinator: Facciabene, Andrea
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.